Lilly’s Humalog Authorized Generic Will Not Quash Price Pressure
Eli Lilly has announced plans to introduce a generic version of its Humalog insulin lispro in the US at a 50% discount to the brand’s list price. However, political pressure is continuing to mount over the lack of availability of cheaper alternatives.
You may also be interested in...
Novo Nordisk will launch US authorized generics of its NovoLog and NovoLog Mix at half the price of the brands from the start of 2020.
Eli Lilly has launched its authorized generic of its own Humalog (insulin lispro) brand in the US, at a 50% discount to the list price of the original.
In response to FDA draft guidance reclassifying certain NDA “drugs” as BLA “biologics,” Eli Lilly is asking the FDA to clarify whether regulatory mechanisms exist for biological product sponsors to introduce ‘second versions’ of their innovative biological products.